Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Aug;47(3):e35-7.
doi: 10.1093/labmed/lmw037. Epub 2016 Jul 4.

Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery

Affiliations
Case Reports

Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery

Alexa J Siddon et al. Lab Med. 2016 Aug.

Abstract

Congenital factor X deficiency is an extremely rare coagulation disorder that can place patients at risk for spontaneous hemorrhage or excessive bleeding in the setting of trauma or invasive procedures. Given the rarity of this disorder, there is little published guidance on how best to prevent or treat bleeding. Herein, we report a case of a 56-year-old white man with congenital factor X deficiency who was scheduled for major neurosurgery and who was treated perioperatively with 4-factor prothrombin complex concentrate (4F-PCC). Doses of 4F-PCC at 15 U per kg, administered immediately preoperatively and once at 24 hours postoperatively, allowed for successful completion of an anterior cervical discectomy and fusion without excessive bleeding. Moreover, no thromboembolic complications were observed. As such, given the wide availability of 4F-PCC, it may be considered as a first-line therapy and an alternative to fresh frozen plasma for factor X deficiencies, particularly in high-risk operative cases.

Keywords: Congenital factor X deficiency; blood banking; coagulation; neurosurgery; prothrombin complex concentrate; transfusion medicine.

PubMed Disclaimer

References

    1. Brown DL, Kouides PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008;14:1176-1182. - PubMed
    1. Unold D, Tormey CA. Clinical applications of 4-factor prothrombin complex concentrate: a practical pathologist’s perspective. Arch Pathol Lab Med. 2015;139:1568-1575. - PubMed
    1. News release. Washington, DC: Food and Drug Administration. FDA approves first factor X concentrate to treat patients with rare hereditary bleeding disorder. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm468038.htm. Accessed June 6, 2016.
    1. van Veen JJ, Hampton KK, Maclean R, et al. Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy. Blood Transfus. 2007;5:203-209. - PMC - PubMed
    1. Lin W, Zhou J, Wang T, et al. Surgical treatment for a paraplegic patient induced by congenital factor X deficiency. Int J Clin Exp Med. 2015;8:13403-13407. - PMC - PubMed

Publication types

Substances